Arkansas Clinical Trials Report — June 2026

For Arkansans considering participation in clinical research, June 2026 presents both urgent deadlines and exciting new opportunities. A total of 42 clinical trials across the state are slated to conclude within the next 90 days, meaning the window for enrollment is rapidly closing. This includes 6 studies that are actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Individuals living with certain health conditions should also act quickly to explore trials with impending deadlines. Research focusing on a range of conditions, from neurological disorders to cardiovascular health, are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Attention-deficit/hyperactivity disorder
• Asthma
• Bladder cancer
• Atrial fibrillation
• Cardiac arrhythmias
• Bipolar disorder I or II with a major depressive episode
• Atopic dermatitis
• Bleeding
• Bronchopulmonary dysplasia
• Burn injury

Major Research Initiatives Launch Across Arkansas

This month, Arkansas welcomed 8 new clinical trials, offering fresh avenues for participation in medical advancements. While slightly fewer than the 10 trials that opened in May 2026, these new studies include several significant Phase 2 and Phase 3 drug trials from major pharmaceutical companies and research institutions. These initiatives provide Arkansans access to cutting-edge treatments for widespread health challenges like obesity, type 2 diabetes, migraine, and crucial vaccine development for infants.

• Pfizer is sponsoring NCT07629440, a Phase 3 study titled "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants." This substantial trial aims to enroll 3,230 participants globally to evaluate the safety and immune response of a new vaccine designed to protect against pneumonia, meningitis, and ear infections in infants.
• For individuals experiencing migraines, Kallyope Inc. is leading two important Phase 3 trials. NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," is a randomized, double-blind study targeting 1,800 participants to assess the effectiveness and safety of a new acute migraine treatment. Additionally, NCT07674654, "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine," will enroll 1,000 participants to further evaluate the safety and tolerability of intermittent use of elismetrep for migraine attacks.
• Those living with obesity or overweight and type 2 diabetes mellitus may be interested in NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)." Sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, this Phase 3, randomized, double-blind study plans for 1,100 participants to assess the long-term efficacy, safety, and tolerability of aleniglipron over 76 weeks.
• AstraZeneca is sponsoring NCT07664553, "A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin." This trial aims to enroll 600 participants to evaluate a new treatment option for adults with type 2 diabetes already on insulin therapy.
• For individuals with obesity and cardiovascular risk factors, BioAge Labs, Inc. is conducting NCT07656727, "A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102." This study, with 160 participants, seeks to understand the effects of BGE-102 on inflammation biomarkers, which may improve obesity and cardiovascular health.

New Research Opportunities Across Conditions

The 8 new trials opening this month in Arkansas cover a diverse range of health conditions, with a strong focus on metabolic health, pain management, and infectious disease prevention. The most common conditions addressed by these new studies include:

• Acute migraine
• Burn injury
• Chronic weight management
• Migraine
• Obesity
• Obesity and cardiovascular risk
• Overweight
• Pneumococcal disease
• Respiratory distress of newborn
• Respiratory distress syndrome (neonatal)

In terms of intervention types, drug trials lead the way, accounting for 5 of the new studies. There is also 1 new biological trial and 1 new device trial, indicating a breadth of research approaches.

Geographic Reach: Little Rock Leads, Other Cities Expand Access

Arkansas's clinical research landscape continues to be robust, with 694 clinical trials currently recruiting across 36 cities and 325 research sites statewide. This month, the majority of new research initiatives are concentrated in the state's capital, Little Rock, which saw 6 new trials open. However, opportunities are also expanding in other parts of the state:

• Fayetteville (1 new trial)
• Jonesboro (1 new trial)
• Rogers (1 new trial)

This distribution ensures that residents in various regions of Arkansas have access to cutting-edge research, even as Little Rock remains a central hub for clinical investigations.

Healthy Volunteers and Diverse Demographics Welcome

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 8 new trials launched this month, 2 are actively seeking healthy volunteers. Statewide, a total of 51 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Clinical trials in Arkansas are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 3 include children as participants, and 7 include older adults, ensuring that research benefits diverse age groups. Industry sponsors are driving significant research efforts this month, with 6 new trials sponsored by pharmaceutical companies such as Kallyope Inc., AstraZeneca, BioAge Labs, Inc., Pfizer, and Gasherbrum Bio, Inc. Academic institutions, including the University of Arkansas and Arkansas Children's Hospital Research Institute, are also contributing with 2 new trials.

As we move through June, the focus will remain on the ongoing enrollment in these significant Phase 2 and Phase 3 trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across Arkansas.